Oct 172014
The
U.S. FDA approved the first two drugs proven to slow progression of
idiopathic pulmonary fibrosis (IPF): pirfenidone (Esbriet by Roche,
which bought Intermune) and nintedanib (Ofev by Boehringer Ingelheim) on
Wednesday October 15. Both drugs will offer new hope for patients,
and new pain to the insurance companies and the government who pay for
them.
